Compare BioNano Genomics Inc (BNGO) vs Diageo plc (DEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Diageo plc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Diageo plc trades at $93.46 (market cap $53.05B). The key difference: Diageo plc is far larger — about 3883.6× BioNano Genomics Inc's market cap, and Diageo plc pays a 3.5% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DEO | |
|---|---|---|
Market Cap | $13.66M | $53.05B |
Sector | Health | Technology |
52-Week High | $4.92 | $115.33 |
52-Week Low | $1.06 | $72.47 |
Enterprise Value | $16.26M | $72.54B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Diageo (DEO) trades at $93.47, down 3.75% on the day, amid mixed earnings and a $1 billion cost-cutting plan announced in August 2026. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentals reveal a P/E of 30.47, net income margin of 8.84%, and recent earnings beats in Q4 2025 and Q2 2026, offset by a Q2 2025 miss. Revenue dipped to $19.6 billion in 2026, with North America weakness pressuring results.
The outlook is cautiously optimistic, driven by cost savings and strategic shifts under CEO Dave Lewis, but risks include regional sales volatility and high debt. Analyst consensus leans buy (48.65%), with price targets suggesting upside, though execution on the turnaround plan is critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
